{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:29:06Z","timestamp":1767979746985,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00535-020-01684-w","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T15:03:57Z","timestamp":1587654237000},"page":"722-730","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Nonalcoholic fatty liver disease: impact on healthcare resource utilization, liver transplantation and mortality in a large, integrated healthcare system"],"prefix":"10.1007","volume":"55","author":[{"given":"Thomas Gerard","family":"Cotter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Holmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Gilroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jake","family":"Krong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"key":"1684_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"1684_CR2","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328\u201357.","journal-title":"Hepatology"},{"key":"1684_CR3","doi-asserted-by":"crossref","unstructured":"Cotter TG, Rinella ME. Nonalcoholic Fatty Liver Disease 2020\u2014The state of the disease. Gastroenterology. 2020;Feb 13\u00a0[Epub ahead of print].","DOI":"10.1053\/j.gastro.2020.01.052"},{"key":"1684_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123\u201333.","journal-title":"Hepatology"},{"key":"1684_CR5","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol. 2018;69:896\u2013904.","journal-title":"J Hepatol"},{"key":"1684_CR6","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/hep.30161","volume":"69","author":"D Kim","year":"2019","unstructured":"Kim D, Li AA, Perumpail BJ, et al. Changing trends in etiology-based and ethnicity-based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States. Hepatology. 2019;69:1064\u201374.","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"1684_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/ajt.14559","volume":"18","author":"WR Kim","year":"2018","unstructured":"Kim WR, Lake JR, Smith JM, et al. OPTN\/SRTR 2016 annual data report: liver. Am J Transpl. 2018;18(Suppl 1):172\u2013253.","journal-title":"Am J Transpl"},{"key":"1684_CR8","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/tri.13358","volume":"31","author":"R Adam","year":"2018","unstructured":"Adam R, Karam V, Cailliez V, et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR)\u201450-year evolution of liver transplantation. Transpl Int. 2018;31:1293\u2013317.","journal-title":"Transpl Int"},{"key":"1684_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","volume":"129","author":"LA Adams","year":"2005","unstructured":"Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113\u201321.","journal-title":"Gastroenterology"},{"key":"1684_CR10","doi-asserted-by":"publisher","first-page":"e7382","DOI":"10.5812\/hepatmon.7382","volume":"13","author":"ME Ghamar Chehreh","year":"2013","unstructured":"Ghamar Chehreh ME, Vahedi M, et al. Estimation of diagnosis and treatment costs of non-alcoholic Fatty liver disease: a two-year observation. Hepat Mon. 2013;13:e7382.","journal-title":"Hepat Mon"},{"key":"1684_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2007.10.024","volume":"134","author":"SE Baumeister","year":"2008","unstructured":"Baumeister SE, Volzke H, Marschall P, et al. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology. 2008;134:85\u201394.","journal-title":"Gastroenterology"},{"key":"1684_CR12","doi-asserted-by":"publisher","first-page":"e004318","DOI":"10.1136\/bmjopen-2013-004318","volume":"4","author":"ZM Younossi","year":"2014","unstructured":"Younossi ZM, Zheng L, Stepanova M, et al. Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study. BMJ Open. 2014;4:e004318.","journal-title":"BMJ Open"},{"key":"1684_CR13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/MCG.0000000000000071","volume":"49","author":"ZM Younossi","year":"2015","unstructured":"Younossi ZM, Zheng L, Stepanova M, et al. Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease. J Clin Gastroenterol. 2015;49:222\u20137.","journal-title":"J Clin Gastroenterol"},{"key":"1684_CR14","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577\u201386.","journal-title":"Hepatology"},{"key":"1684_CR15","doi-asserted-by":"crossref","unstructured":"Allen AM, Van Houten HK, Sangaralingham LR, et al. Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large U.S. claims database. Hepatology. 2018;68:2230\u20132238.","DOI":"10.1002\/hep.30094"},{"key":"1684_CR16","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846\u201354.","journal-title":"Hepatology"},{"key":"1684_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"1684_CR18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/MCG.0000000000000567","volume":"51","author":"M Sayiner","year":"2017","unstructured":"Sayiner M, Otgonsuren M, Cable R, et al. Variables associated with inpatient and outpatient resource utilization among medicare beneficiaries with nonalcoholic fatty liver disease with or without cirrhosis. J Clin Gastroenterol. 2017;51:254\u201360.","journal-title":"J Clin Gastroenterol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-020-01684-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-020-01684-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-020-01684-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T23:54:46Z","timestamp":1619135686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-020-01684-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1684"],"URL":"https:\/\/doi.org\/10.1007\/s00535-020-01684-w","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,23]]},"assertion":[{"value":"2 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TGC, LD, JH, JK have no relevant disclosures. RG has received consultant fees from Salix, Gilead, Novartis; and has been on advisory committees for Salix, Gilead, and Novartis. MC has received grant\/research support from Gilead, Conatus, Galectin; consultant fees from Gilead, Metacrine, Enterome, Novartis, AbbVie, Intercept, NGM Bio; and has been on an Advisory Committee for Gilead.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}